Capan-1 / Capan-1-luc Orthotopic Mouse Model Service for Pancreas Cancer

The Capan-1 / Capan-1-luc orthotopic mouse model for pancreas cancer delivers something few human xenografts can: a BRCA2-deficient pancreatic ductal adenocarcinoma growing in its native organ, accessible to serial, whole-animal bioluminescence measurement. Alfa Cytology brings this model to your program as a fully supported preclinical service — authenticated cell supply, surgical orthotopic implantation, scheduled luciferase imaging, randomized treatment arms, and meticulous endpoint pathology — so every study produces defensible in vivo evidence aligned with your development goals.

Overview of Capan-1 / Capan-1-luc Orthotopic Mouse Model for Pancreas Cancer

Capan-1 is one of the best-characterized human pancreatic ductal adenocarcinoma cell lines in existence. It was established from a liver metastasis of a 40-year-old Caucasian male patient, with tumor tissue first propagated through nude mice before in vitro culture was derived. Its defining molecular feature is the absence of functional BRCA2: the line carries the c.6174delT frameshift allele, producing a truncated protein that loses its RAD51-interacting and DNA-repair domains, which places Capan-1 at the center of homologous-recombination-deficiency research and PARP-inhibitor drug development. The line additionally harbors an activating KRAS G12V mutation and a mutated TP53, while retaining ductal characteristics such as mucin secretion and expression of the cystic fibrosis transmembrane conductance regulator (CFTR).

Fig 1. Genome-wide Transcriptome Analysis of modified Capan-1 cells. (Bozza, Matthias, et al., 2020)

Biologically, Capan-1 grows deliberately — reported doubling times of roughly 60 to 80 hours make it one of the slower PDAC lines, a trait that proves advantageous in orthotopic work. Implanted into the pancreatic parenchyma of immunodeficient mice, the cells establish invasive ductal-type adenocarcinomas at a measured pace, offering an extended window for therapeutic intervention and making the model especially valued in studies of antibody–drug conjugates, DNA-damaging agents, and rational combinations. The luciferase-tagged variant, Capan-1-luc, converts this slow-burn biology into a quantitative asset: tumor establishment and burden can be verified and tracked non-invasively by bioluminescence after D-luciferin administration, giving intra-animal longitudinal data that endpoint-only measurements cannot provide.

Cell Line Information: Capan-1 / Capan-1-luc

Documented attributes of the Capan-1 parental line and its luciferase-engineered counterpart, Capan-1-luc, are summarized below, based on public cell bank records and the peer-reviewed literature.

Our Services

Alfa Cytology operates the Capan-1 / Capan-1-luc orthotopic platform with the patience this slow-growing biology demands — combining careful cell husbandry, sterile surgical technique, scheduled imaging, and rich endpoint pathology into one seamless preclinical service, so your program captures the full value of a BRCA2-deficient model without operational overhead.

Workflow of Capan-1 / Capan-1-luc Orthotopic Mouse Model Construction

A successful Capan-1 orthotopic study rewards careful planning: slow in vitro expansion, deliberate surgical implantation, and patient monitoring over an extended timeline. The standardized sequence below can be tailored in cell number, strain, and schedule to fit each program’s objectives.

1. Cell Line Expansion and Quality Release: Because Capan-1 grows slowly and recovers gradually from cryopreservation, cultures are expanded well in advance with viable floating cells retained, and study release requires STR-confirmed identity, negative mycoplasma testing, and — for Capan-1-luc — verified in vitro luciferase activity.
2. Host Animal Preparation: Female nude or NSG mice, typically 6–8 weeks of age, are health-screened on arrival and acclimatized for at least one week before surgery, ensuring a stable baseline for the demanding orthotopic procedure.
3. Surgical Orthotopic Implantation: Under aseptic conditions with microsurgical technique, the pancreas is exteriorized through a small abdominal incision and 1 × 10⁶ Capan-1 / Capan-1-luc cells in a 25–50 µL PBS/Matrigel suspension are injected into the pancreatic parenchyma or tail, after which the abdominal wall and skin are closed in layers.
4. Post-Operative Care and Engraftment Check: Mice recover with warming and post-surgical analgesia per approved protocols, and initial bioluminescence imaging after D-luciferin injection — complemented by palpation and high-resolution ultrasound — confirms successful engraftment at a stage when the tumor is not yet externally measurable.
5. Baseline Quantification and Randomization: Photon-flux readings are used to allocate animals across control and treatment cohorts with balanced starting tumor burdens, protecting statistical power from the outset.
6. Extended Serial Monitoring: Given the line’s slow growth, bioluminescence imaging is performed on a regular cadence (typically weekly) over a prolonged study window, alongside body weight and clinical health scoring, capturing kinetics that caliper-based models would miss entirely.
7. Test Article Administration: Compounds are dosed per the sponsor-approved regimen — intraperitoneal, intravenous, or oral routes supported — with the extended treatment window of this model suiting fractionated dosing, ADCs, and combination schedules alike.
8. Terminal Analysis and Reporting: At endpoint, primary pancreatic tumors are excised and weighed, abdominal organs are examined for metastatic spread, and tissues are processed for H&E and immunohistochemical staining; the consolidated report integrates imaging curves, tumor metrics, and pathology into a single interpretive package.

Fig 2. Capan-1 / Capan-1-luc orthotopic mouse model construction workflow.

Case Study-Capan-1 / Capan-1-luc Orthotopic Mouse Model Development

Alfa Cytology has executed the Capan-1 / Capan-1-luc orthotopic model in preclinical programs focused on DNA-damaging agents, targeted therapeutics, and combination strategies. In such studies, luciferase-tagged tumors established in the pancreas of immunodeficient mice have been followed by serial imaging across randomized treatment arms, with results compiled into reports that integrate longitudinal imaging, tumor metrics, and histopathological confirmation. Client-specific findings remain confidential and are released only under suitable agreements — reach out to us to request an anonymized case summary or to discuss a study configuration tailored to your therapeutic hypothesis.

Why Choose Alfa Cytology?

Working with a slow-growing, BRCA2-deficient line like Capan-1 demands a CRO that respects the biology rather than fights it. Alfa Cytology brings exactly that mindset to the orthotopic platform — pairing technical rigor with scheduling discipline to deliver data that stands up to scientific scrutiny.

• Advanced cell husbandry suited to slow-growing lines, including careful handling of viable floating populations and extended expansion timelines.
• Microsurgical orthotopic implantation with high engraftment consistency in the pancreatic parenchyma of nude and NSG mice.
• Luciferase-verified reporter cells and calibrated imaging protocols that detect and quantify tumors long before palpable onset.
• Extended study windows that accommodate fractionated dosing, ADCs, and combination regimens without schedule pressure.
• Terminal packages uniting tumor weights, dissemination mapping, and H&E/IHC pathology in a single coherent deliverable.
• Strictly preclinical, confidentiality-first execution with milestone updates and a named study scientist as your single contact.

Contact Us

If your pancreas cancer program requires the unique biology of a BRCA2-deficient model in an orthotopic setting, Capan-1 / Capan-1-luc is the platform built for that question — and Alfa Cytology is ready to put it to work for you. Contact us today for a tailored proposal and timeline, or reach out to us to arrange a technical consultation with our modeling team.

For research use only. Not intended for any clinical use.